The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

The following is a summary of “Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...